Samuel Agresta

2021

In 2021, Samuel Agresta earned a total compensation of $1.8M as Chief Medical Officer at Foghorn Therapeutics, a 72% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$257,100
Option Awards$1,124,004
Salary$428,500
Total$1,809,604

Agresta received $1.1M in option awards, accounting for 62% of the total pay in 2021.

Agresta also received $257.1K in non-equity incentive plan and $428.5K in salary.

Rankings

In 2021, Samuel Agresta's compensation ranked 6,425th out of 12,415 executives tracked by ExecPay. In other words, Agresta earned more than 48.2% of executives.

ClassificationRankingPercentile
All
6,425
out of 12,415
48th
Division
Manufacturing
2,750
out of 5,505
50th
Major group
Chemicals And Allied Products
1,214
out of 2,375
49th
Industry group
Drugs
1,082
out of 2,096
48th
Industry
Pharmaceutical Preparations
784
out of 1,546
49th
Source: SEC filing on April 29, 2022.

Agresta's colleagues

We found three more compensation records of executives who worked with Samuel Agresta at Foghorn Therapeutics in 2021.

2021

Adrian Gottschalk

Foghorn Therapeutics

Chief Executive Officer

2021

Allan Reine

Foghorn Therapeutics

Chief Financial Officer

2021

Carl Decicco

Foghorn Therapeutics

Chief Scientific Officer

News

In-depth

You may also like